Selecta Biosciences

Selecta Biosciences, 3SBio ink agreement for gout

Wednesday, June 18, 2014

Selecta Biosciences, a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, has entered into an exclusive license with 3SBio, a biotechnology company researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

[Read More]